Promising Efficacy of Zanubrutinib + Venetoclax Treatment in Patients with High-Risk Treatment-Naïve CLL/SLL with Del 17p and/or TP53 Mutation

Zanubrutinib is a next-generation, selective BTK inhibitor designed to have high BTK specificity and minimize off-target effects. In this MEDtalk, Paolo Ghia, Professor, Università Vita-Salute San Raffaele di Milano, presents the preliminary results in patients with del 17p and/or TP53 mutation who received zanubrutinib + venetoclax combination treatment in the SEQUOIA trial.